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Abstract		Many	studies	show	that	daily	consumption	of	high-fiber	diet	is	associated	with	a	reduced	risk	of	developing	kidney	stones,	inflammatory	disease,	colon	cancer	and	other	malignancies,	obesity,	type	II	diabetes,	and	cardiovascular	disease.		Dietary	fibers	are	non-digestible	polysaccharides	that	are	composed	of	complex	carbohydrates.	Based	on	their	relative	solubility	in	water,	dietary	fibers	can	be	divided	into	insoluble	and	soluble	forms.		An	important	property	of	insoluble	fibers	is	their	ability	to	bind	with	carcinogens,	mutagens,	and	other	toxic	chemicals	that	are	formed	during	digestion	of	food	and	eliminate	them	through	the	feces.		Soluble	fibers	can	often	be	degraded	to	short-chain	fatty	acids,	such	as	butyrate,	propionate,	and	acetate	by	microbial	fermentation.	This	review	discusses	mechanisms	of	action	of	fibers	and	their	beneficial	effects	on	the	GI	tract	as	well	as	on	other	organs.				Among	short-chain	fatty	acids,	butyrate	has	been	most	extensively	studied	and	the	effects	of	sodium	butyrate	on	cell	culture	and	animal	models	are	discussed	in	order	to	emphasize	its	potential	value	in	prevention	of	certain	diseases.						
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1.			Introduction		 There	is	much	evidence	from	epidemiologic,	and	intervention	studies	that	show	health	benefits	of	daily	consumption	of	high-fiber	diet	fibers	in	humans.		These	health	benefits	include	reducing	the	risk	of	developing	kidney	stones	(Sorensen	et	al.,	2014),	inflammatory	disease(Andoh	et	al.,	2003),	colon	cancer	and	other	cancers	(Wong	et	al.,	2006),	obesity,	type	II	diabetes,	and	cardiovascular	disease	(Lattimer	and	Haub,	2010).			However,	the	exact	type	and	optimal	amount	of	indigestible	dietary	carbohydrates	that	bring	about	protective	events	are	not	well	understood.	The	Institute	of	Medicine	Food	and	Nutrition	has	proposed	a	distinction	between	two	types	of	fibers	dietary	fibers	and	added	fibers.		However,	this	distinction	is	vague	and	it	is	difficult	to	evaluate	their	respective	health	benefits.		The	only	demonstrable	difference	between	the	two	is	the	presence	of	lignin	in	the	dietary	fiber	but	not	in	the	added	fiber.		Dietary	fibers	are	defined	as	non-digestible	polysaccharides	largely	composed	of	complex	carbohydrates.		Based	on	their	relative	solubility	in	water,	dietary	fibers	can	be	divided	into	insoluble	and	soluble	forms.		Soluble	fibers	absorb	water	to	form	a	gel	in	the	intestine,	and	with	the	exception	of	Psyllium	are	more	ready	fermentable	by	the	colon	bacteria	than	insoluble	fibers.		Several	types	of	soluble	fibers,	upon	absorbing	water,	can	form	a	gel	in	the	intestine	and	are	more	readily	fermentable	by	the	colon	probiotic	bacteria	than	insoluble	fibers.		However	not	all	water-soluble	fibers	can	form	gels.	The	process	of	gel	formation	is	complex	and	there	is	a	need	for	better	understanding	of	the	physico-chemical	properties	of	dietary	fibre	at	different	sites	of	the	GI	tract	(Grundy	et	al.,	2016)	Most	dietary	fibers	commonly	found	in	food	contain	both	insoluble	and	soluble	components	and	their	proportion	may	differ	depending	upon	the	diet.		For	example,	fresh	fruits	and	vegetables	contain	more	soluble	than	insoluble	fibers,	whereas	cereals	contain	more	insoluble	than	soluble	fibers	(Otles	and	Ozgoz,	2014).		Dietary	fibers	include	arabinoxylan,	inulin,	pectin,	bran,	cellulose,	hemi	cellulose,	beta-glucan,	and	resistant	starch	(Lattimer	and	Haub,	2010).		Soluble fibers contain pectins, beta-glycan, gums, 
guar fibers, inulin, and resistant starch, whereas insoluble fibers include lignin, cellulose and hemicellulose.                                                                                                                                  
 An	important	property	of	insoluble	fibers	is	their	ability	to	bind	with	carcinogens,	mutagens,	and	
	 4	other	toxic	chemicals	formed	during	digestion	of	food,	allowing	their	subsequent	removal	through	the	feces.	In	contrast,	soluble	fibers	can	form	a	substrate	for	microbial	fermentation	in	the	colon,	leading	to	the	production	short-chain	fatty	acids,	such	as	butyrate,	propionate,	and	acetate	by	fermentation	in	the	colon.		The	amounts	of	short-chain	fatty	acids	formed	during	this	fermentation	depend	upon	the	exact	site	of	fermentation,	levels	of	fibers	in	the	diet,	gut	transition	time,	and	composition	of	the	colonic	microbiome.				 This	review	discusses	mechanisms	of	differential	actions	of	soluble	and	insoluble	fibers	in	producing	beneficial	effects	on	the	GI	tract	as	well	as	other	organs.		Among	short-chain	fatty	acids,	butyrate	has	been	most	extensively	investigated	and	its	effects	in	cell	culture	and	in	animal	models	are	discussed	in	more	detail	in	order	to	illustrate	its	potential	value	in	prevention	of	certain	diseases.		
	
2.			Mechanisms	of	Action	of	Dietary	Fibers		 The	mechanisms	of	action	of	fiber	depend	upon	the	type	of	fiber.		The	ability	of	insoluble	fibers	to	bind	with	several	toxic	chemicals	including	carcinogens	and	mutagens,	allows	these	harmful	materials	to	be	eliminated	through	the	feces.		The	main	beneficial	feature	of	soluble	fibers	is	their	ability	to	be	converted	to	short-chain	fatty	acids	by	their	fermentation	by	probiotic	bacteria	in	the	lower	colon	(Ferguson	and	Harris,	1996).		These	short-chain	fatty	acids	include	butyrate,	acetate,	and	propionate;	however,	butyrate	is	considered	as	the	major	factor	in	maintaining	colonic	homeostasis	with	respect	to	various	diseases	(Galvez	et	al.,	2005).		Butyrate	is	a	4-carbon	fatty	acid	that	is	rapidly	absorbed	from	the	gut.			Exposure	to	sodium	butyrate	can	lead	to	modification	of	histones	by	acetylation,	phosphorylation	of	other	proteins,	and	methylation	of	DNA	thereby	modifying	genomic	expression.		Propionate	after	absorption	from	the	intestine	inhibits	cholesterol	synthesis	and	is	primarily	accumulated	in	the	liver,	whereas	acetate	after	absorption	into	the	blood	stream	increases	the	synthesis	of	cholesterol	(Wong	et	al.,	2006).		
	 5	The	potential	value	of	butyrate	in	prevention	of	certain	diseases	is	suggested	by	studies	performed	in	cultured	cells	and	animals.		Isolated	cells	have	been	directly	exposed	to	varying	concentrations	(1-5	mM)	(Giuliano	et	al.,	1999,	Stoilov	et	al.,	2000)	whereas	animals	were	often	injected	intraperitoneally	with	doses	50-1200	mg/kg	of	body	weight	(Liu	et	al.,	2015,	Kanika	et	al.,	2015,	Gagliano	et	al.,	2014,	Sun	et	al.,	2013).		These	high	levels	may	not	be	not	relevant	for	humans.	
	
3.			Butyrate	and	Cancer		 The	ability	of	butyrate	to	retard	cancer	initiation	was	accidently	discovered	while	investigating	the	effect	of	dibutyryl	cyclic	AMP	on	neuroblastoma	cells	in	which	sodium	butyrate	was	used	as	a	control.		While	dibutyryl	cyclic	AMP	induced	terminal	differentiation	in	neuroblastoma	cells,	sodium	butyrate	alone	caused	growth	inhibition	in	these	tumor	cells	(Prasad	and	Hsie,	1971).		In	addition,	sodium	butyrate	enhanced	the	cell	killing	effects	of	X-radiation,	chemotherapeutic	agents,	and	cyclic	AMP	stimulating	agents	(Prasad,	1979).	The	first	review	on	diverse	biological	action	of	butyric	acid	was	published	in	1980.		Since	then	hundreds	of	articles	have	been	written	on	growth	inhibitory	effects	of	butyric	acid	on	various	cancer	cells.		
	
3.1			Acetylation	of	histones,	phosphorylation	of	proteins,	and	methylation	of	DNA	by	sodium	butyrate	
			 Sodium	butyrate	inhibited	histone	deacetylase	leading	to	hyperacetylation	of	these	basic	proteins	and	loosening	of	their	attachment	to	DNA.	This	allowed	increased	transcription	of	genes	and	caused	apoptosis	in	cancer	cells	(Gospodinov	et	al.,	2012,	Luhrs	et	al.,	2002,	Smith	et	al.,	1998).		In	cultured	fibroblasts,	sodium	butyrate	treatment	increased	methylation	of	DNA	(Boffa	et	al.,	1994).		Sodium	butyrate	regulates	methylation	of	DNA	differently	in	normal	cells	and	transformed	cells	induced	by	Simian	viruses-40	and	gamma-irradiation	(de	Haan	et	al.,	1986).		Treatment	with	sodium	butyrate	enhanced	phosphorylation	of	retinoblastoma	pRb	protein	and	caused	apoptosis	in	human	vestibular	Schwannoma	cells	in	culture	(Mitra	et	al.,	2012).		Sodium	butyrate	treatment	enhanced	phosphorylation	
	 6	of	tyrosine	in	erythroleukemic	cells.		It	also	caused	hyperphosphorylation	of	tyrosine	in	several	proteins	and	led	to	activation	of	MAP	kinase	(ERK-1)	leading	to	apoptosis	in	cancer	cells	(Rivero	and	Adunyah,	1996).			
3.2			Regulation	of	microRNAs	by	sodium	butyrate	in	cancer	cells	
	 	MicroRNAs	(miRs)	are	evolutionarily	conserved	small	non-coding	single-stranded	RNAs	of	approximately	22	nucleotides	in	length	and	are	present	in	all	living	organisms	(Lee	et	al.,	1993,	Wightman	et	al.,	1993,	Londin	et	al.,	2015,	Macfarlane	and	Murphy,	2010).		The	synthesis	of	miRs	involves	multiple	biochemical	steps.		Most	miRs	are	transcribed	by	RNA	polymerase	II	(Pol	II),	while	some	are	transcribed	by	RNA	polymerase	III	(Pol	III)	from	the	non-coding	region	of	the	DNA	to	generate	primary	miRs	(pri-miRs).		Pri-miRs	then	undergo	a	nuclear	cleavage	by	ribonuclease	III	Drosa	in	the	nucleus	leading	to	generation	of	precursor-miRs	(pre-miRs)	that	move	to	the	cytoplasm.		Here	they	are	further	cleaved	by	ribonuclease	III	Dicer	to	form	mature	single-stranded	miRs	with	the	help	of	another	protein	argonaute	(Ago)	(Hutvagner	et	al.,	2001,	Lee	et	al.,	2003,	Denli	et	al.,	2004,	Macfarlane	and	Murphy,	2010).		Each	miR	is	able	to	bind	to	its	complimentary	sequence	in	the	3′-untranslated	region	(3′-UTR)	of	a	specific	mRNA,	leading	to	degradation	of	the	mRNA	transcript,	and	this	prevents	translation	of	the	message	into	the	corresponding	protein.		By	this	means,	miRs	can	prevent	the	translation	of	pro-apoptotic	or	anti-apoptotic	proteins	from	their	respective	mRNAs,	depending	upon	whether	they	receive	injurious	or	protective	signals.		 Tissue	containing	sporadic	human	colon	cancer	cells	have	several-fold	elevated	levels	of	miR-92a	compared	to	adjacent	normal	colon	tissue.		However,	treatment	of	human	colon	cancer	cells	with	butyrate	attenuated	the	levels	of	pri-miR-17-92a,	a	precursor	of	mir-92a,	and	miR-92a,	and	its	target	protein	c-myc	(Macfarlane	and	Murphy,	2010).		Reduction	of	levels	of	miR-92a	led	to	decreased	levels	of	c-myc.		Overexpression	of	miR-92a	reversed	the	inhibitory	effects	of	butyrate	on	colon	cancer	cells.		Sodium	butyrate	treatment	also	enhanced	the	expression	of	miR-203	and	this	prevented	the	translation	
	 7	of	the		NEDD9	gene	(which	is	found	in	neural	precursor	cells	and	down-regulated	during	development,	but	highly	expressed	in	some	tumor	types),	induced	apoptosis,	growth	inhibition,	and	prevented	colony	formation	and	cell	invasion	by	tumor	cells(Han	et	al.,	2016).		Treatment	of	breast	cancer	cells	with	sodium	butyrate	up-regulated	the	expression	of	miR-31	which	led	to	suppression	of	the	levels	of	polycomb	group	(PcG)	protein	BM11	and	induction	of	cellular	senescence	(Cho	et	al.,	2015).		Thus,	by	up-	or	down-regulation	of	specific	miRs,	butyrate	can	effectively	block	colonic	tumor	progression.				
4.			Sodium	Butyrate	and	Inflammatory	Disorders		 Sodium	butyrate	suppressed	colonic	inflammation	by	inducing	T	cell	apoptosis	and	inhibited	interferon-gamma	levels	in	cultured	colonic	mucosal	cells	derived	from	patients	with	ulcerative	colitis	(Zimmerman	et	al.,	2012).	Butyrate	treatment	induced	differentiation	of	colonic	regulatory	T	(Treg)	cells	that	play	an	important	role	in	suppression	of	inflammatory	responses	(Furusawa	et	al.,	2013).		In	the	rat	model	of	colitis,	administration	of	sodium	butyrate	increased	the	number	of	Treg	cells	in	the	peripheral	blood	and	enhanced	the	levels	of	the	anti-inflammatory	cytokine	IL-10	in	plasma.		Sodium	butyrate	also	suppressed	the	levels	of	pro-inflammatory	IL-17	in	both	plasma	and	colonic	mucosa	leading	to	elimination	of	the	inflammatory	lesion	(Zhang	et	al.,	2016a).		Butyrate	also	inhibited	pro-inflammatory	cytokine-induced	activation	of	NF-kappaB	(Andoh	et	al.,	2003).		A	low-fiber	diet	aggravated	the	inflammatory	response	in	an	ovalbumin-induced	allergic	reaction	in	mice,	whereas	a	high-fiber	diet	significantly	reduced	the	allergic	symptoms	(Zhang	et	al.,	2016b).		
5.			Butyrate	and	Neurodegenerative	Diseases			 In	addition	to	acting	as	an	inhibitor	of	histone	deacetylase,	butyrate	also	functions	as	a	ligand	for	a	subset	of	G-protein-coupled	receptors	(Bourassa	et	al.,	2016).			Using	pathways	mediated	by	butyrate,	fiber	metabolism	in	the	gut	could	alter	gene	expression	in	other	organs	including	the	brain.		The	reported	anti-depression	effect	of	sodium	butyrate	may	be	mediated	by	altering	the	expression	of	several	genes	
	 8	that	include	upregulation	of	transthyretin	(Ttr)	and	downregulation	of	the	serotonin	2A	receptor	(Htr2A).		In	a	rat	model	of	depression,	treatment	with	sodium	butyrate	causes	hypermethylation	of	DNA	that	is	mediated	by	demethylation-facilitating	enzymes	such	as	ten-eleven	translocation	methylcytosine	dioxygenase	1	(TET1)	(Wei	et	al.,	2014).	Sodium	butyrate	treatment	attenuated	cerebral	ischemic	injury	in	mice	by	normalizing	levels	of	lipid	peroxidation,	superoxide	dismutase	(SOD),	and	IL-1b,	IL-alpha,	IL-8.		Such	treatment	also	inhibited	apoptosis	most	likely	by	decreasing	levels	of	caspase-3	and	Bax	(Sun	et	al.,	2015).			 Spinocerebellar	ataxia	type	3	(SCA3)	is	an	autosomal	dominant	neurodegenerative	disease	caused	by	polyglutamine-expanded	ataxin-3.		In	transgenic	mice	expressing	disease-causing	ataxin-3-Q79,	treatment	with	sodium	butyrate	reversed	ataxin-3-Q79-induced	histone	hypoacetylation	and	transcriptional	inhibition	and	reduced	the	symptoms	of	the	disease,	increasing	overall	survival	rate	(Chou	et	al.,	2011).		Sodium	butyrate	reduced	glial	fibrillary	acidic	protein	(GFAP)	content	in	both	primary	human	astrocytes	and	astrocytoma	cells,	and	stimulated	the	reorganization	of	the	intermediate	filament	network	(Kanski	et	al.,	2014).		This	observation	is	important	because	the	dysregulation	of	GFAP	gene	expression	can	lead	to	the	aggregation	of	GFAP,	a	hallmark	of	astroglial	inflammation,	found	in	human	leucodystrophy	(Alexander	disease).			 Dentatorubral-pallidoluysian	atrophy	(DRPLA)	is	a	progressive	neurodegenerative	disease	caused	by	the	expansion	of	the	terminal	polyglutamine	of	the	atrophin-1	protein.		In	transgenic	mice	(Atro-118Q)	expressing	the	mutant	human	atrophin-1	gene,	treatment	with	sodium	butyrate	reversed	hypoacetylation,	improved	motor	function,	and	extended	the	lifespan	(Ying	et	al.,	2006).		Over-expression	of	alpha	synuclein	gene	or	mutation	in	alpha-synuclein	gene	is	an	important	factor	in	the	pathogenesis	of	Parkinson’s	disease.		Treatment	with	sodium	butyrate	of	dopaminergic	neurons	expressing	increased	levels	of	both	the	wild-type	alpha-synuclein	gene	or	the	mutated	alpha-synuclein	gene	found	in	familial	Parkinson’s	disease,	and	prevented	DNA	damage	by	rescuing	DNA	repair	enzymes,	thereby	protecting	neurons	(Paiva	et	al.,	2017).		
	 9	In	the	mouse	model	of	spinal	muscular	dystrophy	(SMA),	sodium	butyrate	treatment	increased	the	levels	of	SMA	protein	in	motor	neurons	of	the	spinal	cord	and	improved	the	clinical	symptoms	of	SMA	(Chang	et	al.,	2001).		
6.			Sodium	Butyrate	and	Diabetes		 Because	of	its	ability	to	inhibit	histone	deacetylase,	butyrate	has	been	suggested	as	a	treatment	for	diabetes	(Khan	and	Jena,	2015).		In	support	of	this	proposal,	sodium	butyrate	has	been	found	to	enhance	beta-cell	development,	proliferation,	differentiation,	and	function	and	reduce	diabetic-related	microvascular	complications	(Christensen	et	al.,	2011).		Sodium	butyrate	application	enhanced	renal	function	and	prevented	fibrosis,	apoptosis	and	DNA	damage	in	the	kidney	of	juvenile	diabetic	rats	(Khan	and	Jena,	2014a).		Butyrate	also	decreased	plasma	glucose,	HBA1c,	and	improved	plasma	insulin	levels	in	these	rats	(Khan	and	Jena,	2014b).			In	addition,	sodium	butyrate	treatment	reduced	plasma	glucose,	HbA1c,	insulin	resistance,	lipid	abnormality,	and	glucogenesis	in	a	manner	comparable	to	the	commonly	used	drug	metformin	(Khan	and	Jena,	2016).		Sodium	butyrate	markedly	reduced	diabetes-induced	loss	of	learning	ability,	memory,	and	endothelial	function	in	streptozotocin	treated	diabetic	rats	with	vascular	dementia	(Sharma	and	Singh,	2011).		The	development	of	anti-islet-cell	autoimmunity	generally	precedes	diabetes	type1.		Dietary	fiber-generated	butyric	acid	can	be	protective	against	type	1	diabetes	by	causing	inhibition	of	the	production	of	anti-islet-cell	autoantibodies	(Endesfelder	et	al.,	2016).		In	a	rat	insulinoma	cell	line	(RINm5F),	treatment	with	sodium	butyrate	induced	differentiation,	increased	cellular	insulin	levels	and	insulin	production,	and	expression	of	insulin	mRNAs	(Swarovsky	et	al.,	1994).		Propionate,	another	small	fatty	acid	that	is	generated	during	fermentation	of	soluble	fiber,	did	not	produce	any	parallel	beneficial	effects	in	streptozotocin-induced	diabetic	rats	(Cameron-Smith	et	al.,	1994).				
7.			Sodium	Butyrate	and	Cardiovascular	Disease	
	 10		 Treatment	of	ApoE	knockout	mice	with	sodium	butyrate	slowed	the	progression	of	atherosclerosis	in	the	aorta	by	reducing	adhesion	and	migration	of	macrophages	and	increasing	the	stability	of	the	plaque	(Aguilar	et	al.,	2014).		It	also	reduced	oxidative	and	inflammatory	events	at	the	lesion	site	by	decreasing	NADPH	oxidase	and	decreasing	NFκB	activation	(Aguilar	et	al.,	2016).			
8.		Propionate	and	Acetate		 Propionate	and	acetate	are	other	short-chain	fatty	acids	that	are	generated	during	fermentation	of	dietary	fibers	in	the	colon.		Propionate	has	been	implicated	in	lowering	lipids,	serum	cholesterol	levels,	and	reducing	the	incidence	of	cancer	(Hosseini	et	al.,	2011).		Propionate	administration	increased	the	release	of	peptide	YY	(PYY)	and	glucan	like	peptide-1	(GLP-1)	from	cultured	human	colonic	cells,	and	in	a	randomized,	controlled	24-week	study	involving	60	overweight	adults,	significantly	reduced	weight	gain,	intra-abdominal	adipose	tissue	distribution,	hepatocellular	lipid	content.		In	addition,		there	was	evidence	of	improved	insulin	sensitivity	in	this	population	(Chambers	et	al.,	2015).		Colonic	production	of	propionate	may	play	an	important	role	in	reducing	reward-based	eating	behavior	via	striatal	pathways,	independent	of	changes	in	the	levels	of	PYY	and	GLP-1	(Byrne	et	al.,	2016).		However,	the	half	life	of	propionate	in	humans	is	less	than	3	hr,	which	may	limit	clinical	utility	(Walter	et	al.,	1989).	Sodium	acetate	induced	apoptosis	in	colorectal	cancer	cells	(Oliveira	et	al.,	2015).	Like	propionate,	sodium	acetate	administration	enhanced	the	levels	of	PYY	and	GLP-1,	and	it	also	suppressed	TNF-alpha	in	hyperinsulinemic	women	(Freeland	and	Wolever,	2010).		Also	parallel	to	propionate,	sodium	acetate	reduced	appetite	(Frost	et	al.,	2014).		It	has	been	suggested	that	sodium	acetate	could	replace	sodium	bicarbonate	on	an	equimolar	basis	for	use	in	medical	toxicology	(Neavyn	et	al.,	2013).		The	plasma	half-life	of	acetate	is	about	2	minutes	in	sheep	(Al-Mamun	et	al.,	2009).		
	
9.			The	Potential	Value	and	Limitations	of	Butyrate	in	Disease	Prevention		
	 11			 Production	of	butyrate	during	fermentation	of	primarily	soluble	fibers	is	a	continual	process	in	the	lower	colon,	and	thus	butyrate	could	play	a	role	in	the	prevention	of	a	range	of	human	illnesses,	such	as	cancer,	diabetes,	cardiovascular	diseases,	and	inflammatory	disorders.		Furthermore,	butyrate	may	also	be	useful	as	a	tool	both	to	investigate	the	molecular	mechanisms	underlying	these	diseases	and	in	the	development	of	related	pharmacological	therapeutic	analogs.			The	therapeutic	value	of	exogenously	administered	sodium	butyrate	is	limited	by	its	very	short	plasma	half-life.		In	mice	and	rabbits,	half	-life	of	sodium	butyrate	in	the	blood	was	less	than	5	min.		In	humans,	the	elimination	curve	of	sodium	butyrate	has	two	components:	a	very	rapid	elimination	slope	yields	a	half-life	of	0.5	min,	whereas	a	slower	elimination	slope	provides	a	half-life	of	13.7	min	(Daniel	et	al.,	1989).			However,	the	biological	half-life	of	short	chain	fatty	acids	may	be	extended	by	their	administration	as	esters	such	as	the	inulin	ester	(Polyviou	et	al.,	2016).		Although	the	therapeutic	doses	of	sodium	butyrate	can	be	achieved	by	slow	i.v	infusion,	its	extreme	unpleasant	smell	makes	this	fatty	acid	unlikely	to	be	used	in	any	disease	treatment.		
	
10.			Conclusions	and	Summary		 In	2015,	the	Academy	of	Nutrition	and	Dietetics	recommended	a	daily	consumption	of	total	fiber	of	14	g	per	1000kcal	or	25	g	for	adult	women	and	38	g	for	adult	men.	This	was	based	on	reports	demonstrating	protection	by	dietary	fiber	against	coronary	heart	disease	(Dahl	and	Stewart,	2015).		This	recommendation	is	also	likely	to	be	relevant	for	protection	against	other	diseases.	The	mean	daily	intake	of	dietary	fiber	by	the	US	population	is	about	17g/day	(Dahl	and	Stewart,	2015).		High	intake	of	dietary	fiber	has	also	been	associated	with	a	reduced	incidence	of	colorectal	cancer	as	well	as	improving	overall	intestinal	health.		While	most	experimental	evidence	is	correlative	rather	than	unambiguously	demonstrating	a	causal	relation,	the	ability	of	insoluble	fibers	to	bind	with	mutagens	and	carcinogens,	increasing	their	elimination	through	the	feces,	together	with	the	production	of	beneficial	short-chain	fatty	acids	by	fermentation	of	soluble	fibers,	may	form	the	basis	of	the	significant	overall	health	impact	of	
	 12	dietary	fiber.		These	combined	properties	are	likely	lead	to	reduce	the	incidence	of	colorectal	cancer	and	other	malignancies	as	well	as	non-neoplastic	diseases,	such	as	diabetes,	cardiovascular	disease	and	immune	disorders.		Despite	their	short	half-life	in	the	plasma,	fiber-generated	short-chain	fatty	acids,	as	they	are	generated	for	prolonged	periods	during	digestion,	are	likely	to	be	beneficial	in	reducing	the	incidence	of	specific	diseases.							This	research	did	not	receive	any	specific	grant	from	funding	agencies	in	the	public,	commercial,	or	not-for-profit	sectors.		
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Figure	1	Dietary	fibers	and	their	fermentation	products	affecting	health	
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